Gallacher Capital Management LLC bought a new position in shares of Cabot Corporation (NYSE:CBT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 7,765 shares of the specialty chemicals company's stock, valued at approximately $646,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC lifted its holdings in shares of Cabot by 55.0% during the 1st quarter. CWM LLC now owns 600 shares of the specialty chemicals company's stock valued at $50,000 after purchasing an additional 213 shares in the last quarter. Curat Global LLC bought a new stake in Cabot in the 1st quarter valued at $83,000. Farther Finance Advisors LLC lifted its position in Cabot by 1,346.4% in the 1st quarter. Farther Finance Advisors LLC now owns 1,620 shares of the specialty chemicals company's stock valued at $136,000 after acquiring an additional 1,508 shares in the last quarter. GAMMA Investing LLC lifted its position in Cabot by 26.1% in the 1st quarter. GAMMA Investing LLC now owns 1,700 shares of the specialty chemicals company's stock valued at $141,000 after acquiring an additional 352 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Cabot by 26.8% in the first quarter. Nisa Investment Advisors LLC now owns 2,317 shares of the specialty chemicals company's stock valued at $193,000 after purchasing an additional 489 shares in the last quarter. Institutional investors own 93.18% of the company's stock.
Cabot Stock Performance
NYSE CBT traded down $2.22 on Thursday, hitting $75.93. 81,523 shares of the stock were exchanged, compared to its average volume of 424,673. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.96 and a quick ratio of 1.30. The business's fifty day moving average is $75.80 and its 200 day moving average is $80.71. Cabot Corporation has a 52 week low of $71.64 and a 52 week high of $117.46. The company has a market capitalization of $4.08 billion, a PE ratio of 9.82, a P/E/G ratio of 0.70 and a beta of 0.85.
Cabot (NYSE:CBT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The specialty chemicals company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.04. Cabot had a return on equity of 26.76% and a net margin of 11.08%. The firm had revenue of $936.00 million for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the company earned $1.78 earnings per share. The business's revenue for the quarter was down 8.1% compared to the same quarter last year. Research analysts anticipate that Cabot Corporation will post 7.57 EPS for the current fiscal year.
Cabot Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 29th will be paid a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.37%. Cabot's dividend payout ratio (DPR) is currently 23.29%.
Wall Street Analyst Weigh In
CBT has been the topic of several research reports. Wall Street Zen cut Cabot from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. UBS Group cut their price target on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th.
Read Our Latest Report on Cabot
Cabot Company Profile
(
Free Report)
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Featured Stories

Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.